Rare Disease Advisor: Reagan-Udall Foundation: Recommendations for Rare Disease Endpoints

A new report from the Reagan-Udall Foundation for the Food and Drug Administration (FDA) has distilled longstanding challenges in rare disease drug development into 20 specific recommendations, aiming to consolidate years of regulatory dialogue into an agenda for change at a time when the FDA’s own rare disease infrastructure may finally be positioned to act on it.

Read more